

**StemRIM Announces Patent Registration (Canada) for the Use of the
HMGB1 Fragment Peptide, Redasemtide,
as an Additional Therapeutic Indication for Cardiomyopathy, Old
Myocardial Infarction, and Chronic Heart Failure Caused Thereby**

Osaka, Japan, July 13, 2026 – StemRIM Inc. (TSE:4599, President and CEO: Masatsune Okajima; “StemRIM” or “Company”) announces that a medical use patent for the “Regeneration-Inducing Medicine™” development candidate, Redasemtide, indicated for cardiomyopathy, old myocardial infarction, and chronic heart failure caused thereby, will soon be registered in Canada.

Title of Invention : Therapeutic agent for cardiomyopathy, old myocardial infarction,
and chronic heart failure
Region : Canada
Application No. : CA 3051825
Registration No. : To be determined
Applicant : StemRIM Inc., The University of Osaka

This patent is intended to expand the indications for Redasemtide, which is currently under development. Use patents covering Redasemtide for the treatment of cardiomyopathy, old myocardial infarction, and/or chronic heart failure caused thereby have already been granted in the United States and Mexico. With the grant of the present patent, we believe that the granting of this patent will ensure the possibility of developing a drug for cardiomyopathy, old myocardial infarction, and/or chronic heart failure caused thereby in the North American region.

Cardiomyopathy is a disease characterized by abnormality of the myocardium, leading to impaired cardiac function, which significantly affects patients' quality of life. Therefore, early detection and appropriate treatment are considered critically important. The global market for this condition is projected to reach \$1.9 billion in 2023 and \$3.0 billion by 2031, with a high growth rate anticipated. Against this backdrop, pharmaceutical companies are actively pursuing the development of therapeutic agents through various approaches.

At our company, a Phase 2 investigator-initiated clinical trial targeting ischemic cardiomyopathy has been initiated in March 2024 at The University of Osaka Hospital. The primary objective of this trial is to evaluate the efficacy and safety of Redasemtide in patients with ischemic cardiomyopathy.

The impact on the financial performance for the fiscal year ending July 31, 2026, is insignificant. We will promptly disclose any additional information that needs to be disclosed.

About StemRIM Inc.

StemRIM Inc. is a biotech venture which began at The University of Osaka with the goal of realizing a new type of medicine called “Regeneration-Inducing Medicine™”. The overall aim is to achieve regenerative therapy effects equivalent to those of regenerative medicine, solely through drug administration, without using living cells or tissues. Living organisms have inherent self-organizing abilities to repair and regenerate tissues that have been damaged or lost due to injury or disease. This ability arises from the presence of stem cells in the body that exhibit pluripotency i.e., can differentiate into various types of tissues. When tissues are damaged, these cells, therefore, exhibit proliferative and differentiative capabilities, promoting functional tissue regeneration. “Regeneration-Inducing Medicine™” is aimed at maximizing the tissue repair and regeneration mechanisms already present in the body. With this aim, StemRIM is currently developing one of its most advanced regenerative medicine products. Specifically, this product is designed to release (mobilize) mesenchymal stem cells from the bone marrow into the peripheral circulation upon administration, thus increasing the number of stem cells circulating throughout the body and promoting their accumulation in damaged tissues. Here, these stem cells should accelerate tissue repair and regeneration.

Certain disease areas expected to benefit from “Regeneration-Inducing Medicine™” include epidermolysis bullosa (EB), acute phase cerebral infarction, cardiomyopathy, osteoarthritis of the knees, chronic liver disease, myocardial infarction, pulmonary fibrosis, traumatic brain injury, spinal cord injury, atopic dermatitis, cerebrovascular disease, intractable skin ulcers, amyotrophic lateral sclerosis (ALS), ulcerative colitis, non-alcoholic steatohepatitis (NASH), systemic sclerosis, and any other areas where treatment with mesenchymal stem cells is promising.

Inquiries:

StemRIM Inc.

Management & Administrator Dept.

E-Mail: stemrim-ir@stemrim.com

X: [@StemRIM_Inc](#)

For more information, please visit the StemRIM website (<https://stemrim.com/english/>)